| domain | best-supported finding | evidence scope (H3F3B-specific versus combined BLBS) | ontology/identifier suggestion | evidence limitation |
|---|---|---|---|---|
| Disease identity | Bryant-Li-Bhoj neurodevelopmental syndrome 2 is the H3F3B-associated subtype of Bryant-Li-Bhoj syndrome; OMIM-classified in 2022 and mapped in Open Targets to MONDO:0030607 (pqac-00000001, pqac-00000005) | H3F3B-specific disease label supported by database mapping; phenotype literature often combines H3F3A and H3F3B | MONDO:0030607; OMIM: 619721; gene: H3F3B / H3-3B | Many publications discuss combined BLBS rather than isolated type 2 |
| Synonyms/nomenclature | Names in current use include Bryant-Li-Bhoj syndrome (BLBS) for the combined disorder and Bryant-Li-Bhoj neurodevelopmental syndrome 2 for the H3F3B form (pqac-00000001, pqac-00000005) | Mixed | Bryant-Li-Bhoj neurodevelopmental syndrome 2; BLBS | No stable broad synonym set beyond OMIM/database naming located in the retrieved evidence |
| Causal gene | Causal gene is H3F3B (also written H3-3B), encoding histone H3.3 histone B (pqac-00000001, pqac-00000005, pqac-00000006) | H3F3B-specific | H3F3B; H3-3B | Some papers use H3-3B and H3F3B interchangeably |
| Inheritance | Most reported cases are heterozygous germline de novo variants; inheritance pattern is best described as autosomal dominant, with newer evidence showing that not all cases are strictly de novo because maternally inherited p.N108S has been reported in the expanded cohort (pqac-00000001, pqac-00000002, pqac-00000007) | H3F3B-specific and combined | Autosomal dominant; de novo germline | Penetrance and recurrence risk are not well quantified; inherited cases appear rare |
| Variant spectrum | H3F3B cases include missense and stop-loss/stop-altering variants; Bryant 2020 reported 13 H3F3B patients with 12 unique H3F3B variants, and Okur 2021 added 6 H3F3B individuals including a stop-loss variant (pqac-00000002, pqac-00000006) | H3F3B-specific | Missense variant; stop-loss variant; heterozygous germline variant | Full variant catalog and ClinVar classifications were not extracted here |
| Population frequency | Variants were absent from 138,632 gnomAD controls in the foundational cohort, supporting rarity (pqac-00000002) | Combined BLBS with included H3F3B variants | Ultra-rare Mendelian disorder | No prevalence or incidence estimates available |
| Core neurodevelopmental phenotype | Developmental delay/intellectual disability is a leading feature; in Okur 2021 all detailed individuals had global developmental delay with motor and speech delay (pqac-00000006), and 2024 authors identify developmental delay/intellectual disability as one of the four most common BLBS features (pqac-00000007) | Combined BLBS; includes H3F3B individuals | HPO term suggestion: developmental delay; intellectual disability; motor delay; speech delay | Exact H3F3B-only frequencies not available in retrieved excerpts |
| Tone/motor phenotype | Hypotonia and broader tonal abnormalities are common; gait difficulty/ataxia and progressive gait ataxia have been described (pqac-00000006, pqac-00000007) | Combined BLBS with H3F3B representation | HPO term suggestion: hypotonia; hypertonia; gait ataxia; gait disturbance | Progression appears variable and is not quantified specifically for type 2 |
| Craniofacial phenotype | Craniofacial anomalies are a major syndrome component; in the expanded cohort, craniofacial anomalies were reported in 86% of individuals with H3-3B variants versus 95% with H3-3A variants (pqac-00000001) | H3F3B-specific comparison available | HPO term suggestion: abnormal facial shape; dysmorphic facies; midface hypoplasia | Specific facial feature frequencies for type 2 were not fully extracted |
| Growth phenotype | Short stature/failure to thrive/abnormal growth are common; Okur 2021 found short stature with failure to thrive in 80%, while the expanded cohort noted 31% undergrowth/overgrowth trajectories for H3-3B variants (pqac-00000006, pqac-00000001) | Mixed, partly H3F3B-specific | HPO term suggestion: short stature; failure to thrive; abnormality of head size | Growth direction and severity vary by cohort and variant |
| Brain and imaging phenotype | Structural brain abnormalities are common, including diminished white matter, hypomyelination, cortical dysplasia, leukoencephalopathy, cortical atrophy, and other MRI anomalies (pqac-00000002, pqac-00000006, pqac-00000007) | Combined BLBS with H3F3B representation | HPO term suggestion: abnormal brain MRI; white matter abnormality; hypomyelination; cortical dysplasia; cerebral atrophy | H3F3B-only imaging frequencies were not provided in the retrieved excerpts |
| Vision/hearing/other systems | Visual impairment and ophthalmologic problems are repeatedly reported; hearing, cardiac, endocrine, and GU anomalies are less consistently supported in later aggregate phenotyping (pqac-00000000, pqac-00000006) | Combined BLBS | HPO term suggestion: visual impairment; hearing impairment; congenital hypothyroidism | Some features may reflect ascertainment or incomplete response rates rather than robust syndrome associations |
| Natural history | Disease course spans neurodevelopmental impairment with possible neurodegenerative progression in a subset; Bryant 2020 reported neurologic degeneration in 21% overall and 3 deaths in a 46-person mixed cohort, while Layo-Carris 2024 emphasizes phenotypic heterogeneity and uncertainty about progression (pqac-00000002, pqac-00000007) | Combined BLBS | Neurodevelopmental disorder; neurodegenerative course in subset | Type-2-specific mortality, survival, and longitudinal staging remain undefined |
| Mechanism: chromatin/protein | Germline H3.3 mutations disrupt DNA, histone, and chaperone interactions; modeling mapped many variants to nucleosome interfaces or regulator-binding regions, supporting altered chromatin function distinct from oncogenic somatic histone mutations (pqac-00000002, pqac-00000003) | Combined BLBS with H3F3B mutant lines included | GO term suggestion: chromatin organization; nucleosome assembly; protein-DNA complex assembly | Most mechanistic work is across mixed H3F3A/H3F3B variants rather than isolated H3F3B/type 2 |
| Mechanism: epigenetic/transcriptional | Patient PTM analysis showed aberrant local mutant-histone PTM patterns, RNA-seq showed upregulated mitosis/cell-division programs, and fibroblasts showed increased proliferation with altered S/G2 phases (pqac-00000003) | Combined BLBS with H3F3B patient fibroblasts included | GO term suggestion: regulation of cell cycle; mitotic cell cycle; histone modification; transcriptional regulation by chromatin | Direct causal links from these molecular findings to each clinical phenotype remain incomplete |
| Cell/tissue involvement | Evidence points especially to nervous system development, neural crest-derived tissues, and glial biology; zebrafish studies showed craniofacial anomalies and Foxd3-derived glial defects (pqac-00000003) | Model-organism evidence for mixed H3.3 biology relevant to BLBS | CL term suggestion: glial cell; neural crest cell; UBERON term suggestion: brain; craniofacial skeleton | No dedicated H3F3B-only animal model was identified in retrieved evidence |
| Diagnostic approach | Diagnosis is currently gene-first: exome/genome sequencing or neurodevelopmental disorder panels detecting heterozygous H3F3B variants, interpreted with phenotype correlation and often brain MRI (pqac-00000006, pqac-00000007) | H3F3B-specific gene, general rare-disease workflow | Molecular genetic testing; H3F3B sequencing; exome sequencing; genome sequencing | No formal consensus diagnostic criteria or biomarker assays were identified |
| Differential diagnosis | Authors note phenotypic overlap with leukodystrophy and other neurodevelopmental disorders with structural brain abnormalities, making genomic testing important for distinction (pqac-00000007, pqac-00000006) | Combined BLBS | Differential term suggestion: leukodystrophy; syndromic neurodevelopmental disorder | Differential diagnosis list is not standardized in the retrieved sources |
| Management | No disease-modifying therapy identified; management is supportive and multidisciplinary, focused on developmental therapies, neurology follow-up, feeding/growth support, ophthalmology, and surveillance guided by symptoms and imaging (pqac-00000007, pqac-00000006) | Combined BLBS applied to type 2 | NCIT/clinical intervention term suggestion: supportive care; physical therapy; occupational therapy; speech therapy; genetic counseling | Published treatment-outcome data are extremely sparse |
| Prevention/counseling | Primary prevention is not established; useful measures are genetic counseling, trio testing to confirm de novo status, recurrence-risk discussion, and consideration of prenatal/preimplantation testing once a familial variant is known (pqac-00000001, pqac-00000007) | H3F3B-relevant Mendelian counseling principles | Genetic counseling; prenatal diagnosis; preimplantation genetic testing | Empiric recurrence risk and mosaicism data are not well defined |
| Epidemiology | Ultra-rare disorder with no population incidence/prevalence estimate located; evidence comes from aggregated case series and matchmaker-style ascertainment rather than registries (pqac-00000002, pqac-00000006, pqac-00000007) | Combined BLBS | Rare disease; case-series evidence | Strong ascertainment bias; no denominator-based epidemiology |
| Prognosis | Prognosis is variable and incompletely defined, ranging from severe developmental disability to later-onset progressive neurologic manifestations; survival data are inadequate for type 2 specifically (pqac-00000002, pqac-00000007) | Combined BLBS | Variable expressivity | No validated prognostic biomarkers or genotype-specific outcome models |
| Model systems | Functional evidence includes patient fibroblasts and zebrafish; fibroblasts showed cell-cycle/proliferation abnormalities, and zebrafish showed craniofacial and glial phenotypes (pqac-00000003) | Combined BLBS/mechanistic | Patient-derived fibroblast model; zebrafish model | No dedicated mammalian H3F3B BLBNS2 model identified in retrieved evidence |


*Table: This table summarizes the best-supported current knowledge for Bryant-Li-Bhoj neurodevelopmental syndrome 2, emphasizing what is specific to H3F3B versus what is only available from combined BLBS cohorts. It is useful as a compact knowledge-base scaffold and highlights key evidence gaps.*